# US 2012/0251505 A1 · HUMAN LYMPHOID TISSUE INDUCER (LTi) CELL COMPOSITIONS AND METHODS OF USE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251505 A1
- Document ID: US20120251505A1
- Status: Published application
- Kind: A1
- Application number: 13/394,010
- Filed: 2010-09-03
- Published: 2012-10-04
- Earliest claimed: 2009-09-04
- Assignees: La Jolla Institute for Allergy and Immunology
- Inventors: Carl F. Ware; Vasileios Bekiaris
- Web page: https://patentgrep.com/patent/US20120251505A1

## CPC

- G01N 33/5047: {Cells of the immune system}
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- C12N 5/0651: {Lymph nodes}
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2502/256: Renal cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides human lymphoid tissue inducer (LTi) cells, methods of producing human lymphoid tissue inducer (LTi) cells, and methods of using human lymphoid tissue inducer (LTi) cells. Such methods include treatment of a subject that would benefit from human lymphoid tissue inducer (LTi) cells, for example, an immunocompromised or immunosuppressed subject.

## Claims

### Claim 1

Isolated or purified human lymphoid tissue inducer (LTi) cells, wherein the LTi cells are characterized by expression of CD4, interleukin (IL)-7 receptor alpha, LTalpha, LTbeta, CD30 ligand, CC chemokine receptor 7 (CCR7), CD45, and Integrin β7 protein or mRNA.

### Claim 2

A culture of human lymphoid tissue inducer (LTi) cells comprising a growth or storage medium, wherein the LTi cells are characterized by expression of CD4, interleukin (IL)-7 receptor alpha, LTalpha, LTbeta, CD30 ligand, CCR7, CD45, and Integrin β7 protein or mRNA.

### Claim 3 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the LTi cells are further characterized by expression of inhibitor of DNA binding 2 (Id2) or retinoid-related orphan receptor gamma (Rorc) protein or mRNA.

### Claim 4 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the LTi cells are further characterized by absence of one or more of: IL-17A, IL-22 CD3, CD14, CD16, CD19, CD56, natural killer (NK)-activating receptor NKp44, CD11c, CD11b, human leukocyte antigen DR-1 (HLA-DR), T cell receptor (TCR)-alpha and -beta chains (TCR alpha/beta), recombination activating gene 1 (Rag1), OX40-ligand, LIGHT (lymphotoxin-like, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, expressed by T lymphocytes), CC chemokine receptor 6 (CCR6), CXC chemokine receptor 5 (CXCR5), B cell marker B220, CD11b or IFN-gamma, protein or mRNA expression.

### Claim 5 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the LTi cells are further characterized by one or more of: inducing or stimulating T cells to produce CC chemokine ligand 21 (CCL21), CC chemokine ligand 19 (CCL19), or CXC chemokine ligand 13 (CXCL13), or inducing or stimulating proliferation or differentiation of myeloid dendritic cells (DC).

### Claim 6 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the LTi cells are further characterized by an ability to migrate to lymph nodes, Peyer's patches, or spleen white pulp.

### Claim 7 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the LTi cells are further characterized by contributing to or participating in restoration or formation of lymph nodes, Peyer's patches, or spleen white pulp.

### Claim 8 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the LTi cells are further characterized by stimulating or inducing stromal cells to upregulate an adhesion molecule.

### Claim 9 (depends on 8)

The lymphoid tissue inducer (LTi) cells of claim 8, wherein the adhesion molecule is intercellular adhesion molecule 1 (ICAM-1 or CD54) or vascular cell adhesion molecule 1 (VCAM-1 or CD106).

### Claim 10 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the LTi cells respond to IL-7.

### Claim 11 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the LTi cells are further characterized by one or more of: ability to differentiate into natural killer (NK) cells, antigen presenting cells (APC), or dendritic cells (DC), and an inability to differentiate into T cells or B cells.

### Claim 12 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the cells are adult cells.

### Claim 13 (depends on 2)

The lymphoid tissue inducer (LTi) cells of claim 2, wherein the cells are co-cultured with human embryonic kidney-293T (HEK-293T, ATCC CRL-11268), NHDF (normal human dermal fibroblasts) or HT-29 (colonic epithelial tumor cell line, ATCC HTB-38) cells, or human embryonic kidney-293T (HEK-293T, ATCC CRL-11268), NHDF (normal human dermal fibroblasts) or HT-29 (colonic epithelial tumor cell line, ATCC HTB-38) cell conditioned medium.

### Claim 14 (depends on 1, 2)

The lymphoid tissue inducer (LTi) cells of claim 1 or 2, wherein the cells are viably maintained or sustained, or are proliferating or increasing in numbers.

### Claim 15

A method of producing human lymphoid tissue inducer (LTi) cells, comprising
a) removing or depleting cells expressing CD3 and CD19 from blood cells of a human donor thereby producing a cell population depleted of cells expressing CD3 and CD19;
b) removing or depleting cells expressing CD41 and CD14 from the cell population thereby producing a cell population depleted of cells expressing CD41 and CD14;
c) contacting the cell population depleted of cells expressing CD3, CD19, CD41 and CD14 with IL-7;
d) co-culturing the cell population with human embryonic kidney-293T (HEK-293T, ATCC CRL-11268), NHDF (normal human dermal fibroblasts) or HT-29 (colonic epithelial tumor cell line, ATCC HTB-38) cells, or a human embryonic kidney-293T (HEK-293T, ATCC CRL-11268), NHDF (normal human dermal fibroblasts) or HT-29 (colonic epithelial tumor cell line, ATCC HTB-38) cell conditioned medium; and
e) selecting cells from the cell population produced by steps a), b) and c) that express one or more of CD4, interleukin (IL)-7 receptor alpha, LTalpha, LTbeta, CD30 ligand, CCR7, CD45, and Integrin β7 protein or mRNA, thereby producing a population of human lymphoid tissue inducer (LTi) cells.

### Claim 16 (depends on 15)

The method of claim 15, comprising selecting cells from the cell population produced by steps a), b) or c) for absence of expression of one or more of IL-17A, IL-22 CD3, CD14, CD16, CD19, CD56, natural killer (NK)-activating receptor NKp44, CD11c, CD11b, human leukocyte antigen DR-1 (HLA-DR), T cell receptor (TCR)-alpha and -beta chains (TCR alpha/beta), recombination activating gene 1 (Rag1), OX40-ligand, LIGHT (lymphotoxin-like, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, expressed by T lymphocytes), CC chemokine receptor 6 (CCR6), CXC chemokine receptor 5 (CXCR5), B cell marker B220, CD11b or IFN-gamma, protein or mRNA expression.

### Claim 17 (depends on 15)

The method of claim 15, comprising selecting cells from the cell population produced by steps a), b) or c) for expression of inhibitor of DNA binding 2 (Id2) or retinoid-related orphan receptor gamma (Rorc) protein or mRNA.

### Claim 18 (depends on 15, 16, 17)

The method of claim 15, 16 or 17, further comprising purifying, isolating or enriching the LTi cells by cell sorting.

### Claim 19 (depends on 15)

The method of claim 15, wherein the human donor is about from 1 hour to 100 years in age.

### Claim 20 (depends on 1, 2)

An in vitro or ex vivo method of expanding or increasing numbers of LTi cells, comprising contacting the cells of claim 1 or 2 with human embryonic kidney-293T (HEK-293T, ATCC CRL-11268), NHDF (normal human dermal fibroblasts) or HT-29 (colonic epithelial tumor cell line, ATCC HTB-38) cells, or a human embryonic kidney-293T (HEK-293T, ATCC CRL-11268), NHDF (normal human dermal fibroblasts) or HT-29 (colonic epithelial tumor cell line, ATCC HTB-38) cell conditioned medium under conditions that expand or increase numbers of LTI cells.

### Claim 21 (depends on 1, 2)

A method of identifying a compound that increases or decreases proliferation, growth, survival, or viability of LTi cells, comprising contacting the LTi cells of claim 1 or 2 with a test compound, and determining whether the test compound increases or decreases proliferation, growth, survival or viability of LTi cells.

### Claim 22 (depends on 21)

The method of claim 21, wherein the test compound is a growth factor, a cytokine, an antibody, or a drug.

### Claim 23 (depends on 21)

The method of claim 21, wherein the test compound comprises a fraction of a cell culture supernatant.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cell culture supernatant comprises a HEK-293T, NHDF or HT-29 cell culture supernatant.

### Claim 25 (depends on 21)

The method of claim 21, wherein the test compound comprises a library of compounds.

### Claim 26 (depends on 25)

The method of claim 25, wherein the library comprises a protein or antibody library.

### Claim 27 (depends on 21)

The method of claim 21, wherein the LTi cells do not express or express a non-functional signaling protein.

### Claim 28 (depends on 27)

The method of claim 27, wherein the signaling protein comprises a ligand, receptor, growth factor, or a cytokine.

### Claim 29 (depends on 21)

The method of claim 21, wherein the LTi cells are mammalian.

### Claim 30 (depends on 1, 2)

A method of treating a subject in need of or that would benefit from LTi cells, comprising administering the LTi cells of claim 1 or 2 to a subject thereby providing the subject with the LTi cells.

### Claim 31 (depends on 30)

The method of claim 30, wherein the subject has a viral infection or compromised lymphoid structures.

### Claim 32 (depends on 30)

The method of claim 30, wherein the subject has a chronic viral infection.

### Claim 33 (depends on 30)

The method of claim 30, wherein the subject is immunocompromised or immunosuppressed.

### Claim 34 (depends on 30)

The method of claim 30, wherein the subject is infected with a herpesvirus or HIV.

### Claim 35 (depends on 30)

The method of claim 30, wherein the LTi cells are autologous to the subject.
